ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA, has received a Notice of Allowance for the USA patent application covering its heat-labile dsDNase product.
With the approval of the new patent in the USA, ArcticZymes is adding a new and valuable asset to its existing and fast growing intellectual property portfolio. While a patent in this patent family has already been approved in South Africa, additional patent applications are pending in the main markets including Europe, USA, Japan, Australia, Canada, Brazil, China, India, South Korea and Russia. The allowed patent in the USA provides for broad protection, covering amongst others the dsDNase itself, methods for removing contaminations from a sample reaction, as well as kits or compositions comprising the dsDNase.
“This latest patent approval secures the existing and future position for our innovative HL-dsDNase product in the USA. We are very excited to have received such an early approval of this patent in one of our main markets. This patent will definitely support our commercial efforts in this region,” says CEO Svein Lien at Biotec Pharmacon.
For further information contact: Head of R&D dr Olav Lanes, tel +47 47414256.